Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPM31510 in older adults with sarcopenia
NCT04999488Phase 1Withdrawn
- Sponsor
- AdventHealth Translational Research Institute
- Start
- Dec 2023
- Primary completion
- Dec 2024
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Sarcopenia comparing Placebo with BPM31510 (2 arms). Primary endpoints: Measurement of skeletal muscle at 28 days and Measurement of platelet CoQ10 level at 28 days. Planned start Dec 2023; status: withdrawn.
02
Drugs
ubidecarenone nanodispersion
03
Conditions
Sarcopenia
Beyond the preview
Go deeper on NCT04999488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04999488.